• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   Home
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • View Item
  •   Home
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

WRN Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects

Date
2017
Author
Martin, George M.
KUBISCH, Christian
SCHINDLER, Detlev
DEGUCHI, Kentaro
EASWAR, T. K. M.
FEDERICO, Antonio
Fox, Amy
GREBE, Theresa A.
STREETEN, Elizabeth
PINA-AGUILAR, Raul E.
POKE, Gemma
Poot, Martin
POSMYK, Renata
Oshima, Junko
HAY, Beverly
NAMPOOTHIRI, Sheela
SEITER, Karen
Yokote, Koutaro
Chanprasert, Sirisak
Lee, Lin
EIRICH, Katharina
Takemoto, Minoru
Watanabe, Aki
Koizumi, Naoko
LESSEL, Davor
Mori, Takayasu
Hisama, Fuki M.
Ladd, Paula D.
ANGLE, Brad
BARIS, Hagit
CHATEAU, Antoinette
Ozturk, Sukru
Palanduz, Sukru
Cefle, Kıvanç
Metadata
Show full item record
Abstract
Werner syndrome (WS) is a rare autosomal recessive disorder characterized by a constellation of adult onset phenotypes consistent with an acceleration of intrinsic biological aging. It is caused by pathogenic variants in the WRN gene, which encodes a multifunctional nuclear protein with exonuclease and helicase activities. WRN protein is thought to be involved in optimization of various aspects of DNA metabolism, including DNA repair, recombination, replication, and transcription. In this update, we summarize a total of 83 different WRN mutations, including eight previously unpublished mutations identified by the International Registry of Werner Syndrome (Seattle, WA) and the Japanese Werner Consortium (Chiba, Japan), as well as 75 mutations already reported in the literature. The Seattle International Registry recruits patients from all over the world to investigate genetic causes of a wide variety of progeroid syndromes in order to contribute to the knowledge of basic mechanisms of human aging. Given the unusually high prevalence of WS patients and heterozygous carriers in Japan, the major goal of the Japanese Consortium is to develop effective therapies and to establish management guidelines for WS patients in Japan and elsewhere. This review will also discuss potential translational approaches to this disorder, including those currently under investigation. (C) 2016 Wiley Periodicals, Inc.
URI
http://hdl.handle.net/20.500.12627/61646
https://doi.org/10.1002/humu.23128
Collections
  • Makale [92796]

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 


Hakkımızda
Açık Erişim PolitikasıVeri Giriş Rehberleriİletişim
sherpa/romeo
Dergi Adı/ISSN || Yayıncı

Exact phrase only All keywords Any

BaşlıkbaşlayaniçerenISSN

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypesThis CollectionBy Issue DateAuthorsTitlesSubjectsTypes

My Account

LoginRegister

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV